Christopher Raymond
Stock Analyst at Piper Sandler
(3.25)
# 1,071
Out of 4,996 analysts
134
Total ratings
51.82%
Success rate
0.74%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $8 → $9 | $5.54 | +62.45% | 9 | Aug 6, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $82.84 | -15.50% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $137.37 | -16.28% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.87 | +381.28% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $53.85 | +133.98% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $1.89 | +111.64% | 3 | Feb 11, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $220 → $227 | $220.61 | +2.90% | 12 | Jan 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $385.74 | +38.18% | 8 | Jan 27, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,195 → $1,013 | $563.90 | +79.64% | 7 | Jan 27, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $135 → $140 | $29.08 | +381.43% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $76.63 | -6.04% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $1.99 | +553.27% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $6.55 | +1,045.04% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $15.00 | +406.67% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $1.58 | +532.91% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $12.97 | +154.43% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $3.25 | +115.38% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $14.16 | +55.37% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.74 | +45.99% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $8.19 | +205.44% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $272.98 | +5.50% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $38.93 | +5.32% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $42.47 | -34.07% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $81.39 | -50.85% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $6.15 | +1,363.41% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.48 | +3,770.97% | 2 | Mar 13, 2020 |
Ardelyx
Aug 6, 2025
Maintains: Neutral
Price Target: $8 → $9
Current: $5.54
Upside: +62.45%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $82.84
Upside: -15.50%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $137.37
Upside: -16.28%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.87
Upside: +381.28%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.85
Upside: +133.98%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $1.89
Upside: +111.64%
AbbVie
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $220.61
Upside: +2.90%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $385.74
Upside: +38.18%
Regeneron Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $563.90
Upside: +79.64%
Ultragenyx Pharmaceutical
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $29.08
Upside: +381.43%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $76.63
Upside: -6.04%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $1.99
Upside: +553.27%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $6.55
Upside: +1,045.04%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $15.00
Upside: +406.67%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.58
Upside: +532.91%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $12.97
Upside: +154.43%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $3.25
Upside: +115.38%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $14.16
Upside: +55.37%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.74
Upside: +45.99%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $8.19
Upside: +205.44%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $272.98
Upside: +5.50%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $38.93
Upside: +5.32%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $42.47
Upside: -34.07%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $81.39
Upside: -50.85%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $6.15
Upside: +1,363.41%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.48
Upside: +3,770.97%